Featured Event

GHTC is hosting an event "From lab to lives saved: How health innovation at USAID is advancing the journey to self-reliance" on August 14 in Washington, DC. The event will feature a fireside chat with USAID Chief of staff Bill Steiger and panel discussion with staff from the Global Health Bureau and nonprofit and private sector partners.

Learn More

CDC/James Gathany
GHTC Statement on the Okayama Declaration of the G20 Health Ministers Meeting

The Global Health Technologies Coalition is greatly encouraged that yesterday’s Okayama Declaration from G20 Health Ministers contains strong support for investing in research and development initiatives to combat antimicrobial resistance and improve public health preparedness.

Learn More

PATH/Matthew Dakin
GHTC sends FY21 letter to OMB

GHTC sent a letter to the White House Office of Management and Budget (OMB), calling for the administration to sustain and protect global health R&D in the fiscal year 2021 (FY21) budget.

PDF

PATH/Matthew Dakin
GHTC op-ed featured in The Hill

A commentary piece authored by GHTC Director Jamie Bay Nishi on the steady and substantial funding necessary to drive breakthrough innovations for global health threats was featured in The Hill

View

PATH/Wendy Stone
GHTC Director quoted in The Hill on Ebola vaccine development

The Hill quoted GHTC Director Jamie Bay Nishi in an article on Ebola vaccine development. 

View

PATH/Wendy Stone
GHTC Director quoted in The Verge on product development for emerging and infectious diseases

The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.

View
View All News

CDC/James Gathany
GHTC Statement on the Okayama Declaration of the G20 Health Ministers Meeting

The Global Health Technologies Coalition is greatly encouraged that yesterday’s Okayama Declaration from G20 Health Ministers contains strong support for investing in research and development initiatives to combat antimicrobial resistance and improve public health preparedness.

Learn More

PATH
US FDA Approves New TB Drug in Treatment to Cure Practically Incurable XDR-TB

Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.

Learn More

PATH/Mike Wang
President Signs Bill Reinforcing Fight Against Disease Threats. Focus Now Turns to Funding.

This legislation is an important step forward in strengthening our nation’s preparedness against global disease threats. We applaud the Administration and Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiological and nuclear threats, but naturally occurring health threats as well.

View

GHTC
GHTC opens call for nominations for 2019 Innovating for Impact Awards

GHTC has opened nominations for its 2019 Innovating for Impact Awards. Now in its third year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is July 31, 2019.

Learn More

PATH/Eric Becker
Congress Takes Key Step to Reinforce Fight Against Disease Threats. Focus Now Turns to Funding.

The passage of PAHPAI is an important action by Congress to strengthen our nation’s preparedness against global disease threats. We applaud Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiologic and nuclear threats, but naturally occurring health threats as well.

Learn More
View All Announcements
Play: TRICK or TREATment?

To enjoy a bit of fun and mischief this Halloween, we’ve created a game, TRICK or TREATment, to test our readers’ knowledge of global health technologies.

Read More
PATH/Wendy Stone
Research Roundup: Merck Ebola vaccine approved by European regulators, TB funding gap persists, and new NTD detected in Brazil

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Satvir Malhotra
Research Roundup: Global Fund replenishment, FDA allows marketing of first rapid Ebola test, and NIH to launch influenza vaccine research centers

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Carib Nelson
Research Roundup: Bacteria-infected mosquitoes to fight dengue, BARDA to fund Marburg and Ebola vaccines, and saliva test to diagnose malaria

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Matthew Dakin
Research Roundup: Antibody to combat malaria, BARDA to advance Ebola treatment, and UHC High-Level Meeting

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
View Breakthroughs Blog

PATH/Matthew Dakin
GHTC op-ed featured in The Hill

A commentary piece authored by GHTC Director Jamie Bay Nishi on the steady and substantial funding necessary to drive breakthrough innovations for global health threats was featured in The Hill

View

PATH/Wendy Stone
GHTC Director quoted in The Hill on Ebola vaccine development

The Hill quoted GHTC Director Jamie Bay Nishi in an article on Ebola vaccine development. 

View

PATH/Wendy Stone
GHTC Director quoted in The Verge on product development for emerging and infectious diseases

The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.

View

PATH/Katrina Peach
GHTC Director quoted in CIDRAP on FDA approval of a new drug for highly resistant tuberculosis

CIDRAP quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View

PATH/Nguyen Ba Quang
GHTC Director quoted in the Los Angeles Times on FDA approval of a new drug for highly drug-resistant tuberculosis

The Los Angeles Times quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View
View All GHTC in the Media

PATH/Matthew Dakin
GHTC sends FY21 letter to OMB

GHTC sent a letter to the White House Office of Management and Budget (OMB), calling for the administration to sustain and protect global health R&D in the fiscal year 2021 (FY21) budget.

PDF

PATH/Ruhani Kaur
GHTC endorses Comprehensive TB Elimination Act

GHTC joined other advocates in endorsing the Comprehensive TB Elimination Act of 2019, which would enhance tuberculosis (TB) R&D at the National Institutes of Health and facilitate coordination of late stage R&D of new TB diagnostic, treatment, and prevention tools with the Biomedical Advanced Research and Development Authority.

PDF

PATH/Nguyen Ba Quang
GHTC statement on High-Level Meeting on Tuberculosis (TB) delivered at WHA

A statement by GHTC and partners calling on the World Health Organization and member states to close the US$1.3 billion gap in annual TB R&D funding was made at the 72nd World Health Assembly. The statement urges countries to invest in the development of new medicines and technologies to treat multidrug-resistant TB and to facilitate rapid and equitable access to these interventions.

View

PATH/Gabe Bienczycki
GHTC statement on pandemic influenza preparedness delivered at WHA

A statement by GHTC and partners encouraging innovative technologies and approaches to accelerate universal influenza vaccine research and development was made at the 72nd World Health Assembly. This statement recognizes pandemic influenza as a looming global health threat and encourages the World Health Organization and member states to increase investment and collaborative action to accelerate development of a universal flu vaccine.

View

CDC/Melissa Dankel
GHTC statement on UN High-Level Meeting on AMR delivered at WHA

A statement by GHTC and partners noting that innovation and R&D must be at the heart of any agenda to tackle AMR was delivered at the 72nd World Health Assembly. The statement applauds World Health Organization member states for recognizing the need for new antimicrobials, vaccines, and diagnostics, and urges continued progress on commitments made at the United Nations (UN) High-Level Meeting.

View
View All Advocacy Actions

Events

Community Event

David Jacobs
2019 Global Health Security Index
Nuclear Threat Initiative, Johns Hopkins Center for Global Health Security, The Economist Intelligence Unit
Learn More

Community Event

PATH/Gabe Bienczycki
World Health Summit 2019
World Health Summit
Learn More
View All Current & Past Events

Stay Informed

Sign up to receive news and updates from GHTC.
Sign Up Now

Media Inquiries

Marissa Chmiola
Communications Officer
Global Health Technologies Coalition
mchmiola@ghtcoalition.org